FDA Accepts Application for Canagliflozin by Apotex
The FDA has accepted the application for Canagliflozin submitted by Apotex under ANDA210449.
Asset / Drug
Drug and asset intelligence for Janssen with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
SGLT2 Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.